BioScrip Inc. (NASDAQ:BIOS) – Research analysts at Barrington Research lowered their FY2016 earnings estimates for shares of BioScrip in a report released on Wednesday. Barrington Research analyst M. Petusky now anticipates that the brokerage will post earnings per share of ($0.46) for the year, down from their previous forecast of ($0.35). Barrington Research also issued estimates for BioScrip’s Q4 2016 earnings at ($0.11) EPS, Q1 2017 earnings at ($0.13) EPS, Q2 2017 earnings at ($0.10) EPS, Q3 2017 earnings at ($0.08) EPS, Q4 2017 earnings at ($0.05) EPS, FY2017 earnings at ($0.35) EPS and FY2018 earnings at ($0.18) EPS.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Monday, November 7th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The company had revenue of $224.50 million for the quarter, compared to analyst estimates of $223.26 million. The firm’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.38) earnings per share.

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Other research analysts have also recently issued research reports about the stock. Jefferies Group started coverage on shares of BioScrip in a report on Tuesday, November 8th. They set a “buy” rating and a $2.50 target price for the company. Zacks Investment Research cut shares of BioScrip from a “buy” rating to a “hold” rating in a report on Friday, August 12th.

Shares of BioScrip (NASDAQ:BIOS) opened at 1.36 on Monday. BioScrip has a 1-year low of $1.15 and a 1-year high of $3.43. The company has a 50-day moving average of $2.77 and a 200-day moving average of $2.68. The company’s market cap is $160.05 million.

A number of hedge funds have recently made changes to their positions in BIOS. Metropolitan Life Insurance Co. NY purchased a new stake in shares of BioScrip during the second quarter worth approximately $152,000. BlackRock Advisors LLC boosted its stake in shares of BioScrip by 87.8% in the third quarter. BlackRock Advisors LLC now owns 57,715 shares of the company’s stock worth $167,000 after buying an additional 26,989 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of BioScrip during the second quarter worth approximately $176,000. PNC Financial Services Group Inc. boosted its stake in shares of BioScrip by 368.4% in the second quarter. PNC Financial Services Group Inc. now owns 74,362 shares of the company’s stock worth $190,000 after buying an additional 58,486 shares in the last quarter. Finally, M&T Bank Corp purchased a new stake in shares of BioScrip during the second quarter worth approximately $204,000. Hedge funds and other institutional investors own 85.85% of the company’s stock.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

5 Day Chart for NASDAQ:BIOS

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.